Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

PURPOSE: Adavosertib may alter exposure to substrates of the cytochrome P450 (CYP) family of enzymes. This study assessed its effect on the pharmacokinetics of a cocktail of probe substrates for CYP3A (midazolam), CYP2C19 (omeprazole), and CYP1A2 (caffeine). METHODS: Period 1: patients with locally...

Descripción completa

Detalles Bibliográficos
Autores principales: Någård, Mats, Ah-See, Mei-Lin, Strauss, James, Wise-Draper, Trisha, Safran, Howard P., Nadeau, Laura, Edenfield, William J., Lewis, Lionel D., Ottesen, Lone H., Li, Yan, Mugundu, Ganesh M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363032/
https://www.ncbi.nlm.nih.gov/pubmed/37394627
http://dx.doi.org/10.1007/s00280-023-04554-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363032/
https://www.ncbi.nlm.nih.gov/pubmed/37394627
http://dx.doi.org/10.1007/s00280-023-04554-3

Ejemplares similares